Universal flu vaccine enters first human trial
NCT ID NCT06460064
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new universal influenza vaccine called fH1/DSP-0546LP in 144 healthy adults aged 18 to 40. The goal was to check safety and how well the vaccine triggers an immune response. Participants received two shots three weeks apart, with different doses or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fH1/DSP-0546LP (universal influenza vaccine)
- What this could lead to
- If it works, this could lead to a vaccine that protects against many flu strains, reducing the need for yearly shots.
- What could go wrong
- This is a very early Phase 1 trial with only 144 healthy adults, so safety and immune response are still unproven. The vaccine may not work in larger, more diverse populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Vaccinology
Ghent, Corneel Heymanslaan 10, 9000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts